We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this ...
Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...
As for Lilly ( LLY ), Bernstein said its outperform rating “hinges on what they can do with the cash they generate from ...
On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) announced plans to voluntarily withdraw the U.S. accelerated approval for ...
Fintel on MSN1d
Bernstein Initiates Coverage of Gilead Sciences (GILD) with Outperform RecommendationFintel reports that on October 17, 2024, Bernstein initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a Outperform ...
Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...
Medpage Today on MSN4d
Novel Drug Effective Against MASH in Phase II TrialAn investigational oral fatty acid synthase (FASN) inhibitor was associated with significant improvements in metabolic ...
With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...
Gilead Sciences GILD has outperformed the market over the past 20 years by 3.74% on an annualized basis producing an average ...
Zacks.com on MSN2d
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should KnowGilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some ...
On Friday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $84.95 which represents a slight increase of $0.28 or 0.33% from the prior close of $84.67. The stock opened at $84 ...
Houston-based The Normal Anomaly Initiative, a nonprofit with offices in Dallas too that is dedicated to uplifting and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback